Citi Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral

February 12, 2021 7:26 AM EST
Get Alerts ALNY Hot Sheet
Price: $137.77 +0.17%

Rating Summary:
    19 Buy, 12 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 18 | Down: 10 | New: 17
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Citi analyst Joel Beatty downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Buy to Neutral with a price target of $175.00 (from $170.00).

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $165.38 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst PT Change, Downgrades

Related Entities

Citi